Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01451177 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)

A Phase 2 study, sponsored by Aderans Research Institute.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target

NCT01451177: Completed Phase 2 study, sponsored by Aderans Research Institute.

NCT01451177 is a Phase 2 study that has completed, run by Aderans Research Institute. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01451177, a Phase 2 study, has completed, sponsored by Aderans Research Institute.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target

Study Summary

Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.

Interventions

  • BIOLOGICAL Autologous cultured dermal and epidermal cells

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2010-05
Phase Phase 2
Aderans Research Institute

11 total trials

What the finished NCT01451177 record still lists

NCT01451177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 1 intervention - of which Autologous cultured dermal and epidermal cells is the first listed.

NCT01451177 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01451177 about?

NCT01451177 is a clinical study titled "A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)". Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.

What is the current status of trial NCT01451177?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2010-05.

What interventions are being tested in trial NCT01451177?

The interventions under investigation include: Autologous cultured dermal and epidermal cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT01451177?

This trial is sponsored by Aderans Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01451177's enrollment target sits among peer trials

43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01451177, the US trial registry maintained by the National Library of Medicine. NCT01451177 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.